2,3,4,5,6-Pentafluorobenzoyl chloride

We are 2,3,4,5,6-Pentafluorobenzoyl chloride CAS:2251-50-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2,3,4,5,6-Pentafluorobenzoyl chloride
CAS.NO:2251-50-5
Synonyms:2,3,4,5,6-Pentafluorobenzoyl chloride
Pentafluorobenzoyl chloride
Pentafluorobenzoic acid chloride
Molecular Formula:C7ClF5O
Molecular Weight:230.52
 
Physical and Chemical Properties:
Density:1.601
Boiling point:158-159ºC
Index of Refraction:1.453
 
Specification:
Appearance:Colorless to pale yellow transparent liquid
Assay:≥99.0%
Moisture:≤0.2%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Pharmaceutical or pesticide, liquid crystal material intermediates
 

2,3,4,5,6-Pentafluorobenzoyl chloride


Related News: The outlook for a cure is clouded with theoretical uncertainties and high-profile failures. Pharmaceutical giants including Johnson & Johnson, Merck and Pfizer have ditched their projects on unsatisfactory data.380636-50-0 Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.78560-45-9 Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.1-oxido-2 – [(1,3,4-trimetil-4,5-dihidroimidazol-1-ium-2-il) sulfanil] piridin-1-ium, tetrafluoroborato CAS:367252-09-3 INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment.

Related Products
Product Name
ac-asp(otbu)-oh View Details
D-Leucine View Details
(E)-4-(Dimethylamino)But-2-Enoic Acid Hydrochloride View Details
5-(2,4,6-trimethylphenyl)cyclohexane-1,3-dione manufacturer ethyl (1R,2S)-1-amino-2-ethenylcyclopropane-1-carboxylate,sulfuric acid manufacturer 2-Brom-xanthen-9-on manufacturer Glycine methyl ester hydrochloride manufacturer 4-Chloro-3-nitroquinoline manufacturer